CCN1: A sticky issue in myeloma

摘要

In this issue of Blood, Johnson et al report that patients with high CCN1 levels in their marrow who were treated in the Total Therapy 3 trial have a prolonged overall survival and better progression-free survival than patients with lower levels of CCN1.